We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

79 hedge funds and large institutions have $77.2M invested in Concert Pharmaceuticals, Inc. in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more call options, than puts

Call options by funds: $230K | Put options by funds: $161K

7.64% less ownership

Funds ownership: 64.55% → 56.91% (-7.6%)

13% less funds holding

Funds holding: 91 → 79 (-12)

25% less capital invested

Capital invested by funds: $104M → $77.2M (-$26.4M)

26% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 31

46% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 26

Holders
79
Holders Change
-12
Holders Change %
-13.19%
% of All Funds
1.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
23
Reduced
31
Closed
26
Calls
$230K
Puts
$161K
Net Calls
+$69K
Net Calls Change
-$293K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$1.23M
2
ISL
Ingalls & Snyder LLC
New York
+$1.16M
3
Millennium Management
Millennium Management
New York
+$1.16M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$942K
5
GCP
GSA Capital Partners
United Kingdom
+$687K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$7.01M
2
SPIA
Steward Partners Investment Advisory
New York
-$1.71M
3
State Street
State Street
Massachusetts
-$1.67M
4
Nuveen
Nuveen
North Carolina
-$1.39M
5
Northern Trust
Northern Trust
Illinois
-$956K

CNCE Hedge Fund Activity: Q2 2021 in Review

79 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q2 2021, worth a combined $77.2M — down 25% from $104M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of CNCE and 14 opened new positions — a net loss of 12 holders — while 31 trimmed existing stakes and 23 added.

The largest buyer was Morgan Stanley, adding an estimated $1.23M. The largest seller was BlackRock, cutting an estimated $7.01M.

  • 79 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q2 2021, down from 91 in Q1 2021.
  • Funds reported $77.2M of Concert Pharmaceuticals, Inc. stock for Q2 2021, down 25% quarter-over-quarter.
  • 14 funds opened new Concert Pharmaceuticals, Inc. positions in Q2 2021 and 26 closed out, a net change of -12 holders.
  • The largest Concert Pharmaceuticals, Inc. buyer in Q2 2021 was Morgan Stanley, an estimated $1.23M added.
  • The largest Concert Pharmaceuticals, Inc. seller in Q2 2021 was BlackRock, an estimated $7.01M sold.

Based on aggregated 13F filings for Q2 2021.